Trial Profile

Evaluating safety and immunogenicity of a quadrivalent inactived subunit influenza virus vaccine after injection in healthy people aged 3 years old and above: a randomised, double-blind,active-controlled phase III clinical trial

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Quadrivalent inactivated subunit adjuvanted influenza vaccine-Jiangsu Zhonghui Yuantong Biotechnology (Primary)
Indications Influenza virus infections
Focus Adverse reactions; Pharmacodynamics; Registrational

18 Jul 2022 New trial record
07 Jul 2022 Primary endpoint has been met. (The GMT antibody concentration of A1, A3 and two B lineages), as per Results published in the Vaccine
07 Jul 2022 Results published in the Vaccine

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com